Trade RPRX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Royalty Pharma plc Class A (RPRX) is trading at US$63.96, up 0.13% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$27.3B. Over the past 52 weeks, RPRX has traded between US$34.08 and US$64.38. On Syfe you can trade RPRX with $0 commission and add it to your watchlist.
| Previous close | US$63.88 |
|---|---|
| Market cap | US$27.3B |
| P/E ratio | 11.41 |
| 52-week range | US$34.08 – US$64.38 |
| Dividend yield | 1.45% |
| Volume | 3.36M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Royalty Pharma plc Class A
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Year: 2020
Royalty Pharma Q2 Net Income Falls, Revenue Rises
Aug 5, 11:25 AM · MT Newswires
-- Earnings Flash (RPRX) Royalty Pharma plc Reports Q2 Revenue $674.0M
Aug 5, 11:00 AM · MT Newswires
Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday
Jul 22, 1:18 PM · MT Newswires
Royalty Pharma Acquires Royalty Interest in AstraZeneca's Cliramitug
Jul 22, 11:37 AM · MT Newswires
--Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14
Jul 17, 8:23 PM · MT Newswires
Royalty Pharma plc Class A (RPRX) stock is trading at US$63.96, +0.13% from the previous close of US$63.88.
The market cap for Royalty Pharma plc Class A (RPRX) stock is approximately US$27.3B.
The price-to-earnings ratio for Royalty Pharma plc Class A (RPRX) is 11.41, based on the latest reported earnings.
The 52-week high for Royalty Pharma plc Class A (RPRX) stock is US$64.38.
The 52-week low for Royalty Pharma plc Class A (RPRX) stock is US$34.08.
Yes, Royalty Pharma plc Class A (RPRX) pays a dividend. The trailing 12-month dividend yield is 1.45%.
Stay on top of RPRX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
